MaxCyte Expands Stock Capital Amid Cell Therapy Growth

MaxCyte (MXCT) has released an update.

MaxCyte Inc., a leader in cell-engineering technologies, has issued 256,320 shares of common stock under its block admission facility, bringing its total issued stock capital to over 105 million shares. This move is part of the company’s effort to support its long-term incentive plan, which still has over 7.6 million shares available for future issuance. Investors interested in the cell therapy market may find MaxCyte’s strategic stock management and innovative platform technologies noteworthy.

For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.